Abstract The Risk Model is a validated outcome predictor for patients with head and neck squamous cell carcinoma (Brandwein-Gensler et al. in Am J Surg Pathol 20:167-178, 2005; Am J Surg Pathol 34:676-688, 2010 Head and Neck Pathol (2013) 7:211-223 DOI 10.1007/s12105-012-0412-1 in 9 T1N0 patients (6 %) and 9 T2N0 patients (10 %). On multivariable analysis, the Risk Model was significantly predictive of LRR (p = 0.0012, HR 2.41, 95 % CI 1.42, 4.11) and DSS (p = 0.0005, HR 9.16, 95 % CI 2.65, 31.66) adjusted for potential confounders. WPOI alone was also significantly predictive for LRR adjusted for potential confounders with a cut-point of either WPOI-4 (p = 0.0029, HR 3.63, 95 % CI 1.56, 8.47) or WPOI-5 (p = 0.0008, HR 2.55, 95 % CI 1.48, 4.41) and for DSS (cut point WPOI-5, p = 0.0001, HR 6.34, 95 % CI 2.50, 16.09). Given a WPOI-5, the probability of developing locoregional recurrence is 42 %. Given a high-risk classification for a combination of features other than WPOI-5, the probability of developing locoregional recurrence is 32 %. The Risk Model is the first validated model that is significantly predictive for the important niche group of low-stage OCSCC patients.
Introduction
Patients with low-stage oral squamous cell carcinomas (OC-SCC) are usually treated by surgery alone. Yet a certain percentage of these patients develop local recurrence and/or regional lymph node metastasis, and possibly disease-related mortality. There are few large studies of Stage I/II OCSCC that address this issue. Sessions reported disease-specific mortality rates of 25 and 37 % for Stage I and Stage II cancers, respectively [1] . Disease progression and disease-specific mortality rates of 12 and 3 %, respectively, were reported by Jerjes for Stage I/II patients [2] . Disease progression and overall mortality rates of 14.5 and 23.5 %, respectively, were reported by Huang for Stage I/II patients [3] .
The Risk Model was originally proposed in 2005 [4] as an extention and modification of prior multivariable histological models [5] [6] [7] [8] [9] and was recently validated in a new patient cohort in 2010 [10] . The current study tests the hypothesis that the Risk Model has added prognostic value for low-stage OCSCC patients. These data can become the basis for predicting which low-stage patients are significantly at greater risk for locoregional recurrence. Thus lowstage high-risk patients, lacking the traditional indications for adjuvant radiotherapy, may be offered the option of adjuvant radiotherapy based on this novel classification system.
Materials and Methods
With IRB approval, we identified 299 patients with Stage I/II primary OCSCC treated by en-bloc resection at University of Alabama at Birmingham (UAB), Tel-Aviv University (TAU), The Tom Baker Cancer Centre, University of Calgary (UC), Beth Israel Medical Center (BI), Montefiore Medical Center (MMC), University of Manitoba (UM), and New York University Langone Medical Center (NYU). The mechanism for identifying cases at each institution was identical. The pathologist from each center retrospectively reviewed reports on all consecutive head and neck resections, identified target index cases, and retrieved all pathology slides. For a number of sites (UAB, BI, NYU, and UM), it was feasible to continue prospectively identifying index cases. The cohort of 299 patients spanned over two decades and included 95 patients with Stage I/II OC-SCC who were previously reported in 2010 [10, 11] (MMC: n = 44, UM: n = 24, NYU: n = 13. TAU: n = 14), but herein have longer follow-up.
All hematoxylin and eosin stained pathology slides from the resection specimens were uniformly reviewed by MBG, blinded to outcome. All T1 carcinomas had been entirely submitted for histological evaluation. All T2 carcinomas were either entirely or nearly entirely sampled. Hematoxylin and eosin stained deeper levels were examined, when necessary, to resolve any issues. The following malignancies were excluded from study: SCC with depth of invasion under 1 mm, spindle cell variant of SCC, adenosquamous carcinoma, squamous carcinomas with prominent intraductal component, and patients who were seropositive for HIV. Verrucous carcinomas were not excluded, as they represent the prototypical ''low-risk'' SCC. There were only two verrucous carcinomas in this cohort.
All tumors were classified for perineural invasion (PNI), lymphocytic host response (LHR), and worst pattern of invasion (WPOI) according to previously published criteria, and then categorized according to risk level (Table 1 ) [10] . To avoid repetition, the details on how the these variables were assessed will be presented in the ''Discussion''. Maximum depth of invasion was recorded on all carcinomas B1 cm. Resection margins were histologically assessed as follows: margins C5 mm from carcinoma were deemed negative; margins \5 mm were deemed close and positive margins represented ''tumor cut-through''.
Clinicopathologic and demographic information (medical center, age, gender, race, ethnicity, date of surgery, T stage, N stage, adjuvant therapy) were collected and coded in Microsoft Access databases. All surgeries were confirmed as being primary with curative intent. Adjuvant therapy consisted of radiotherapy; no systemic chemotherapy was administered in this low-stage cohort. Additionally, we collected information on alcohol and smoking on 191 and 217 patients, respectively. These data were categorized as (1) alcohol intake (yes/no), (2) ounces of alcohol per week, (3) smoking (yes/no), and (4) number of pack-years. The endpoints assessed were local recurrence and/or regional lymph node metastases (locoregional recurrence, or LRR), disease-specific survival (DSS) and overall survival (OS). LRR was measured from the initial surgery date to the first pathologically documented LRR, versus last follow-up date with disease-free status. DSS was measured from the initial surgery date until disease-related death, versus last live follow-up date or death from causes other than index cancer. DSS was independently adjudicated in all seven medical centers by the physicians involved in the care of these patients. Patients with unknown cause of death were omitted from DSS analysis but included in OS analysis. Patients who were lost to follow-up were censored at the date last known to be alive. We do not expect the Risk Model to predict metachronous cancers; patients developing new primaries were censored at the date of diagnosis of a second tumor, and coded as disease-free with respect to the index tumor. The Microsoft Access databases were combined in Excel and deidentified for statistical analysis. Descriptive statistics was employed to summarize patient baseline characteristics, histological features and disease classification at diagnosis. Continuous data were summarized by using medians and ranges (min and max), categorical data by using frequency counts and percentages. The Chi square test was used for categorical variables, and the Wilcoxon rank sum test was used for continuous variables. Local recurrence and disease specific death are two time-to-event outcomes. The cumulative incidences curves were estimated in a competing risk framework [12] . For the analysis of local recurrence, we treated deaths from causes other than cancer as competing event; for the analysis of disease specific survival, we treated local recurrence and death from other causes as competing risk. The Gray test was used to assess the significance of differences in events across subgroups [12] . Both analyses were applied for the individual variables of WPOI, LHR, PNI, and the combined variables in the Risk Model. Other factors included medical center, gender, age C60 years, resection margin status, tumor stage, and treatment (surgery vs. surgery plus radiotherapy). All covariates adjusted for in the multivariable models were prespecified. Statistical analyses were carried out with SAS version 9.3 and the macro CumInc is used for estimation of the cumulative incidence function. Fine and Gray proportional-hazards model [13] for subdistribution of a competing risk was used. The Receiver Operator Characteristics (ROC) analyses were performed for WPOI and the Risk categories, with respect to LRR and DSS. Alcohol and tobacco use was assessed for their influence on survival outcomes in a subset of data analysis. All reported p values are two sided, and statistical significance was claimed at B0.05.
Results
The study group consisted of 299 patients with primary Stage I/II OCSCC; the clinicopathologic data regarding this cohort is summarized in Table 2 . As can be expected in a multicenter study, there is heterogeneity in the methodology of margin assessment and the definitions of negative margins. This heterogeneity is reflected in the wide range for the rates of resection margin adequacy, defined here as C5 mm (39-81 %, median 59 %). The varying adjuvant radiotherapy rates also reflect different philosophies per institution (6-60 %, median 23 %). The frequency distributions for perineural invasion, pattern of invasion, lymphocytic response, and the risk categories, stratified for tumor stage are detailed in Table 3 . The rate of high-risk tumors was significantly greater in T2 as compared to T1 tumors (p = 0.042), which was due to the significantly greater incidence of perineural invasion (p = 0.0006). Alcohol and smoking intake data was available on a subgroup of 191 and 217 patients, respectively. Smoking was common, the incidences varied from 30 % (Tel Aviv University) to 78 % (University of Alabama at Birmingham). Subgroup analysis of patients with available smoking and alcohol intake data, (191 and 217, respectively) demonstrated no association between smoking or alcohol use and either LRR or DSS. Two hundred ninety-four patients were analyzed for outcome (average follow-up 31 months, Table 4 ). Thirty T1N0 patients (17 %) and 26 T2N0 patients (23 %) developed LRR (average 15 months). No patient developed distant metastasis as a first disease-progression event. Forty patients died; 18 patients (6 %) were independently adjudicated as having died of disease (average 14 months). DSS occurred in nine T1N0 patients (6 %) and nine T2N0 patients (10 %) (average 14 months). All patients who died of disease had experienced prior LRR (p \ 0.0001, Fig. 1 ). There was no significant association between LRR, DSS, and Stage. Twenty-two patients died of other causes.
Univariate analysis of LRR demonstrated that the following variables of interest were significantly associated Tumor depth of invasion (DOI) has been studied extensively as a predictor of occult cervical metastases and disease-progression. Most studies support a cut-off value of 4-5 mm DOI; this value may be used as an indication for elective neck dissection [14] [15] [16] [17] . Prior to the present study, there were no validated prognosticators for Stage I/II OCSCC beyond this 5 mm DOI cut-off. The Risk Model addresses this niche subgroup as a post-resection assessment that can be used to support the recommendation of adjuvant radiotherapy based on the weight of evidence. Multiparameter histological predictive models have been advocated in Europe since the 1970s and tumor pattern of invasion was a consistent component of these models [5] [6] [7] [8] [9] [18] [19] [20] [21] [22] . Other components have included lymphocytic host response, exophytic versus endophytic growth pattern, mitotic rate, degree of keratinization, and nuclear pleomorphism. Jakobsson's original model evaluated 8 variables in a 4-tiered scoring system. This cumbersome system was modified into a four-variable four-tiered system by Bryne [7] [8] [9] . Attempts at validating the Bryne model were not always successful. Problems included small sample size, heterogeneous tumor sites and primary treatment modalities, plus evaluation of different specimen types, as some studies evaluated only biopsies, others only resection specimens, and still others evaluated both biopsies and resection specimens. We published our novel Risk Model in 2005, which extended previous models and also contained some unique features [4] . The Risk Model classified patients into low-, intermediate-, and high-risk groups, and correlated significantly with locoregional This makes a compelling argument for the value of our model. We believe that it is reasonable to offer low-stage high-risk patients the option of adjuvant radiotherapy based on the weight of evidence from this study. However, the present data could not demonstrate any outcome benefit for highrisk patients receiving adjuvant radiotherapy; this may be due to the small numbers of locoregional recurrences. Therefore, the logical next step would be a parallel Phase II study comparing surgery versus surgery plus adjuvant radiotherapy for low-stage, high-risk patients, which would be designed to show promising clinical benefit.
From a practical viewpoint, Table 6 can be used as a ''road map'' with respect to predicting LRR. Given the presence of WPOI-5 in a Stage I/II OCSCC, the probability of developing LRR is almost 42 %. If a Stage I/II OCSCC is classified as high-risk based on a combination of features other than WPOI-5, for example PNI (score = ?1), LHR-2 (score = ?1), and WPOI-4 (score = ?1), total Risk Score of ?3, then the high-risk classification is still significantly predictive, but the probability of LRR drops to 32 %.
One study strength is that the cohort is large and geographically diverse. Another strength is the uniform application of the Risk Model, as all slides were reviewed by one of the investigators (MBG); substantial intrarater agreement (j = 0.77, 95 % CI 0.61, 0.90) has been previously demonstrated [10] . Risk scoring is relatively simple as it is based on examining H & E stained slides from the adequately sampled tumor host interface. It needs to be reiterated that assessment of these histological features requires the study of resection specimens, not biopsies, as the advancing tumor edge is under-sampled in biopsies. Serial ''bread-loafing'' of the resection specimens is preferred, as it aids in the evaluation of WPOI (see below). T1 and small T2 OCSCC should be submitted entirely for histology. If a T2 OCSCC is close to 4 cm in size, then the advancing edge and resection margin planes should be submitted in entirety. The goal of the initial publications [4, 10] was to describe the model and present the subsequent validation on a new cohort of patients, these publications were never intended to guide the practical application of the model. Presently, and prior to any clinical trial, there are surgeons at our institutions who believe that it is reasonable to offer low-stage high-risk patients the option of receiving adjuvant radiotherapy. Surgical pathologists at other institutions who would like to use the Risk Model should first seek out practical training sessions. Real-time multi-headed microscope training sessions improve the reproducibility between pathologists applying the Risk Model [10] . Below, we present some guidance regarding the application to the Risk Model, which is not intended to substitute for training sessions.
The Risk Model is based on the assessment of WPOI, LHR, and PNI; the definitions of these variables and scoring are summarized in Table 1 . Figure 3 represents an algorithm for risk assessment. The point assignments are shown in yellow. As tumors with WPOI-1, WPOI-2, and WPOI-3 all receive the same score of 0, they are indicated in this figure as ''Nonaggressive POI''. Nonaggressive tumors may have either broad pushing fronts, or finger-like pushing fronts, or large ([15 cells) separated islands; the first two phenotypes are relatively rare compared to WPOI-3 tumors. Figure 4 illustrates phenotypes easily recognized as ''Nonaggressive POI''. Tumors with nonaggressive POI can be considered not to extend beyond their perimeter. For example, tumors with interconnected ''strand-like'' islands (Fig. 5) or ''fingerlike'' projections (Fig. 6) that are confined to a perimeter should be interpreted as ''nonaggressive''.
WPOI-4 tumors are defined as having small tumor islands (B15 cells per island) which are discontiguous, or convincingly separated from the main tumor mass; examples are illustrated in Figs. 7 and 8 . WPOI-5 tumors are recognized by a dispersed, discontiguous growth pattern; the degree of tumor dispersion exceeds that seen for WPOI-4 tumors with a defined cut-off of 1 mm. The tumor dispersion distance may be measured between the main tumor and ''the first wave'' of dispersed satellites, or between subsequent, distal waves of satellites. A conservative approach should be adopted when assessing WPOI. When identifying putative WPOI-5 tumor satellites, it is preferable to examine the sections immediately adjacent to the area of interest, to exclude any connecting tumor projections. There are a number of possible histological phenotypes for WPOI-5 tumors; most commonly WPOI-5 tumors are dispersed Fig. 3 Decision tree for evaluating WPOI, PNI, and LHR, and point assignment throughout soft tissue either as tumor strands, small rounded tumor satellites, or large tumor satellites (Fig. 9 ). More rarely, tumors can be classified as WPOI-5 due to either dispersed perineural invasion (Fig. 10) or dispersed lymphovascular tumor emboli (Fig. 11) . A simple method for microscopic measurement is overlaying the pathology slides with millimeter rulers printed on acetate film (See http:// www.vendian.org/mncharity/dir3/paper_rulers).
Perineural invasion is defined as carcinoma that specifically wraps around a nerve. Thus SCC adjacent to nerves, (or ''bumping'' against nerves) are excluded. Large nerves are defined as C1 mm in diameter.
Lymphocytic host response is assessed light microscopically at the advancing tumor edge, and is assessed cumulatively as the overall strongest response. LHR assessment presently does not require quantification of specific lymphocyte populations, however we have previously demonstrated that T cells are the predominant lymphocyte at the tumor advancing edge [23] . Figure 4a demonstrates a carcinoma with strong LHR throughout the advancing tumor interface. Here the LHR also extends into the carcinoma, but this is not requisite for LHR-1. The cutpoint to separate LHR-1 and LHR-1 is that LHR-1 SCC has at least one dense lymphoid nodule per 49 field. A lymphoid nodule is defined as a dense collection of lymphocytes immediately adjacent to carcinoma which comprises at least 50 % of a 209 field, immediately adjacent to carcinoma (Fig. 12) . A tumor with limited LHR has no identifiable lymphoid nodule (Fig. 13) . In this study, we excluded small cancers with depth of invasion (DOI) under 1 mm. Twenty-six T1 OCSCC had DOI between 1 and 4 mm and none of these patients developed locoregional recurrence. However, limited depth of invasion is not independent of the Risk Model; all tumors with DOI of \4 mm were classified as either lowor intermediate-risk. Based on these data, we now conclude that is it reasonable to exclude invasive carcinomas with DOI of \4 mm from risk assessment.
Given the relative rarity of low-stage OCSCC, the only means of accruing a large cohort is to design a multicenter retrospective and prospective study. The pretreatment alcohol and cigarette intake data did vary in completeness; this might be considered relevant as some studies have demonstrated a dose-dependent relationship between pretreatment smoking and decreased OS [24] . However, for low-stage OCSCC, disease-specific mortality (DSM) is more relevant than OS and is very low in the present cohort. Subgroup analysis of patients with available smoking and alcohol intake data (73 and 64 %, respectively), demonstrated no association between smoking or alcohol use and either LRR or DSS. Therefore, it is highly unlikely that incompleteness of the smoking and alcohol data might have impacted our analysis. One study limitation is that data regarding intraoral subsite, and type of locoregional recurrence (local recurrence and/or regional lymph node metastases) were not uniformly collected from all seven centers. With respect to tumor subsite, previous unpublished analyses have demonstrated that the distribution of risk categories varies with anatomic site, but the performance of the model is not affected. We recommend that follow-up studies address the above points.
A limitation of the current risk model is the fact that the definition of LHR is based on a specified size. Does the definition of a lymphoid nodule require adjustment for small T1 carcinomas? In the present study, 15 small T1 SCC were borderline LHR-2/LHR-3, these tumors were ''upgraded'' to LHR-2 (blinded to outcome) as they did not otherwise look like high-risk tumors. Figure 14 represents a schematic of these 15 LHR borderline patients. Based on these data, small T1 SCC C4 mm, with WPOI-3, no PNI, and borderline LHR-2/LHR-3, can be liberally upgraded to LHR-2. However, 2 of 7 patients with T1 SCC C4 mm, WPOI-4, no PNI, and borderline LHR-2/LHR-3 developed LRR. This highlights a potential problem area in the Risk Model, which requires further study.
Prior to the present collaboration, Vered et al. [11] published a cohort of 50 patients with oral SCC, all stages, evaluating the performance of the Risk Model. Multivariable analysis demonstrated that high-risk classification was significantly predictive of local recurrence when adjusted for confounders (age, margin status) (p = 0.022, HR 11.2, 95 % CI 1.4, 87.1). More recently, Rodrigues de Matos et al. [25] applied the risk model to 62 patients with tongue carcinoma, all stages; this study did not address the predictive performance of the model with respect to outcome. They found that limited lymphocytic host response and perineural invasion correlated with positive cervical lymph nodes on presentation (p = 0.034, p = 0.035, respectively).
Conclusion
The Risk Model is the first validated model that is predictive for the important niche group of low-stage OCSCC patients. We report locoregional recurrence and disease-specific mortality rates of 20 and 7 %, respectively. The Risk Model was significantly predictive of LRR (p = 0.0012, HR 2.41, 95 % CI 1.42, 4.11) and DSS (p = 0.0005, HR 9.16, 95 % CI 2.65, 31.66) adjusted for potential confounding variables. Given a WPOI-5, the probability of developing locoregional recurrence is 42 %. Given a high-risk classification for a combination of features other than WPOI-5, the probability of developing locoregional recurrence is 32 %. These data set the stage for the next logical step, which would involve a prospective, randomized Phase II trial to test the hypothesis that patients with low-stage high-risk cancers will benefit from receiving adjuvant radiotherapy. It is reasonable for surgeons to offer patients with low-stage high-risk SCC the option of adjuvant radiotherapy, based on the expectation that these patients are at greater risk for failing a primary surgical approach. However, we caution that surgical pathologists at other institutions who want to use the Risk Model should seek training sessions.
